Articles related to Urology

A community oncologist previewed four ASCO 2026 late-breaking abstracts spanning pancreatic, prostate, lung, and sarcoma, flagging molecular testing infrastructure and toxicity coordination as key implementation questions ahead of the data readout.

Adding niraparib to abiraterone prolonged radiographic progression-free survival in BRCA-mutant metastatic hormone-sensitive prostate cancer, with overall survival data still maturing.

This recent case out of Orange County, CA, is forcing a question: When does a complication cross the line into criminal liability?

“If I can put smarter MRI adjacent to a robotic consult and seamlessly transfer from one image to the next, it allows me to have a very efficient, safe surgery, and ensure that I’ve removed all fibroids.” – Dr. Tamatha Fenster, New York-Presbyterian

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026

“At 10 years, BCF was 38.0% for HDR compared with 10.4% for SBRT.” — Udovicich et al., JAMA Network Open, February 2026